Drug Design At The Peroxisome Proliferator-Activated Receptor


Marketed By :  LAP LAMBERT Academic Publishing   Sold By :  Kamal Books International  
Delivery in :  10-12 Business Days

₹ 5,066

Availability: Out of stock


Delivery :

Product Out of Stock Subscription

(Notify me when this product is back in stock)

  • Product Description

The Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) agonist Rosiglitazone, has recently been withdrawn from the European market and its use has been restricted in the US due to its undesirable effects which were considered to outweigh its benefits. This study explores the two agonist bound conformations of the PPARγ, as exemplified by its binding to Rosiglitazone and that to Farglitazar. Furthermore, it evaluates whether they should be targeted separately in the context of drug design studies. The binding modalities of Rosiglitazone and Farglitazar were studied in great detail and a series of molecules capable of agonist activity at the PPARγ have been designed, with the potential to act as leads in a drug design process.

Product Specifications
SKU :COC84905
Country of ManufactureIndia
Product BrandLAP LAMBERT Academic Publishing
Product Packaging InfoBox
In The Box1 Piece
0 Review(s)